Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06603077 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Avalo Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06603077: Active Phase 2 study of Hidradenitis Suppurativa, sponsored by Avalo Therapeutics.
NCT06603077 is a Phase 2 study of Hidradenitis Suppurativa that is active but no longer recruiting, run by Avalo Therapeutics. The registered enrollment target is 250 participants, below the 593-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06603077, a Phase 2 study of Hidradenitis Suppurativa, is active but no longer recruiting, sponsored by Avalo Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
Primary Outcome
HiSCR75 is defined as at least a 75% reduction in the total abscess and inflammatory nodule count, with no increase in abscess count and no increase in draining fistula count, relative to Baseline.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AVTX-009 Regimen 1
- DRUG AVTX-009 Regimen 2
Study Locations (20)
Florida
- Clinical Site 1029 - Boca Raton
- Clinical Site 1002 - Coral Gables
- Clinical Site 1015 - Maitland
- Clinical Site 1027 - North Miami Beach
- Clinical Site 1013 - Tampa
California
- Clinical Site 1032 - Northridge
- Clinical Site 1019 - Pomona
- Clinical Site 1009 - Sacramento
- Clinical Site 1034 - Santa Monica
Arizona
- Clinical Site 1022 - Scottsdale
- Clinical Site 1037 - Scottsdale
- Clinical Site 1026 - Tucson
Kentucky
- Clinical Site 1031 - Bowling Green
- Clinical Site 1024 - Murray
Massachusetts
- Clinical Site 1042 - Boston
- Clinical Site 1001 - Boston
District of Columbia
- Clinical Site 1011 - Washington D.C.
Georgia
- Clinical Site 1008 - Savannah
Illinois
- Clinical Site 1014 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
What the registry record for NCT06603077 still lists
NCT06603077 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 593-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06603077 names 20 study sites across 9 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06603077 about?
NCT06603077 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa". The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
What is the current status of trial NCT06603077?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2024-09-16. Estimated completion is 2026-04.
What conditions does trial NCT06603077 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06603077?
The interventions under investigation include: Placebo (DRUG), AVTX-009 Regimen 1 (DRUG), AVTX-009 Regimen 2 (DRUG).
Who is sponsoring clinical trial NCT06603077?
This trial is sponsored by Avalo Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06603077 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06603077's enrollment target sits among peer trials
250 18th of 52 higher than 35 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI